Physician profile
Yeva Evin
NPI 1831562347
$2,519.47
in general payments reported to CMS, 2019-2025
12 companies · $852 in 2025
The $852 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $713 · 2022: $370 · 2023: $218 · 2024: $366 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $816.63 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $402.77 | 2021-2022 | |
| Aop Health US, LLC | $335.38 | 2025 | Rapiblyk |
| Alnylam Pharmaceuticals INC. | $305.86 | 2024-2025 | Amvuttra |
| Pfizer INC. | $179.38 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $119.92 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $106.60 | 2021-2022 | |
| Abiomed | $100.04 | 2025 | |
| Csl Behring | $57.92 | 2024-2025 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $33.10 | 2025 | Eliquis |
| Edwards Lifesciences Corporation | $31.15 | 2025 | Konect Resilia |
| Novartis Pharmaceuticals Corporation | $30.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeva Evin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.